Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)
NCT ID: NCT00802906
Last Updated: 2012-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2007-05-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
NCT00418431
Bevacizumab Intravitreal for Myopic Choroidal Neovascularization
NCT00797992
Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)
NCT00370786
Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein Occlusion
NCT03353324
Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
NCT01256580
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs
subthreshold micropulselaser
on demand if leakage is persistent or recurs after initial treatment
bevacizumab
1.5 mg initial intravitreal injection
2
initial selective subthreshold micropulselasercoagulation and on demand if leakage is persistent or recurs
subthreshold micropulselaser
on demand if leakage is persistent or recurs after initial treatment
3
control
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
subthreshold micropulselaser
on demand if leakage is persistent or recurs after initial treatment
bevacizumab
1.5 mg initial intravitreal injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Lens / corneal opacities
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johann Wolfgang Goethe University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael Koss
PI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Koss, MD
Role: PRINCIPAL_INVESTIGATOR
ZAU Department of Vitreoretinal surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ZAU Department of VR surgery
Frankfurt am Main, Hesse, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Koss MJ, Beger I, Koch FH. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond). 2012 Feb;26(2):307-14. doi: 10.1038/eye.2011.282. Epub 2011 Nov 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-RCS-2008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.